Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity
{{output}}
FOXA1 is altered in 10 to 40% of prostate cancers, yet its oncogenic mechanisms remain uncharacterized in vivo. We developed knock-in mouse models representing distinct classes of FOXA1 mutations. Histopathological and multi-omic analyses of prostate tissues a... ...
